Peter,
It appears to me that GNSL qualifies as a trickle play under Rick's narrow definiton of "here & now" reagents and instruments. We seem to be tacitly expanding that to include software/bioinformatics plays such as PCOP (but not ARQL because of its excessive drug discovery angle). It reported recently, and then broke out revenue related to proteomics a few days later.
siliconinvestor.com
siliconinvestor.com
Further, the chart shows these levels to offer support from these levels. Big caveat: it's a few weeks out of lock-up. From the S-1:
"11,785 Immediately after the date of this prospectus
14,364,666 180 days after the date of this prospectus, subject in some cases to volume limitations
2,612,278 At various times after 180 days from the date of this prospectus
The holders of 99% of our capital stock, including our directors and officers, have entered into lock-up agreements under which they have agreed that they will not sell, directly or indirectly, any shares of callable common stock without the prior written consent of UBS Warburg LLC for a period of 180 days from the date of this prospectus, with the exception of family and estate planning transfers."
The date of the prospectus is May 4, 2000.
biz.yahoo.com
Stock has been weak since lock-up expiration. Priced 7 million shares @ $8 on IPO. Per Yahoo! the shares now eligble for trading now include the entire stock outstanding (17M (from above) + 7M (float from IPO) = 24M).
siliconinvestor.com
Popped on a Strong Buy from one of the underwriters, which got it here to the low teens. The trickle portfolio is interested in nibbling ~$11 unless strongly dissuaded.
Cheers, Tuck |
